Margari Niki, Giovannopoulos Ilias, Pouliakis Abraham, Mastorakis Emmanouil, Gouloumi Alina Roxani, Panayiotides Ioannis G, Karakitsos Petros
Second Department of Pathology, University of Athens, School of Medicine, "Attikon" University Hospital, Athens, Greece.
Acta Cytol. 2018;62(2):137-144. doi: 10.1159/000485824. Epub 2018 Jan 16.
To investigate the potential of Classification and Regression Trees (CARTs) for the diagnosis of thyroid lesions based on cell block immunocytochemistry and cytological outcome.
A total of 956 histologically confirmed cases (673 benign and 283 malignant) from patients with thyroid nodules were prepared via liquid-based cytology and evaluated; 4 additional slides were stained for cytokeratin 19 (CK-19), galectin 3 (Gal-3), Hector Battifora mesothelial cell 1 (HBME-1), and thyroglobulin. On the basis of immunocytochemistry and the cytological diagnosis, a CART algorithm was constructed and used for evaluation.
The major important factors contributing to the diagnostic CART model were: cytological outcome, CK-19, Gal-3, and HBME-1. The sensitivity and specificity of the cytological diagnosis were 96.27% and 88.26%, respectively (cut-off: category 3 of The Bethesda System [TBS-3]). The introduction of immunocytochemistry and the CART model increased the sensitivity and specificity to 98.88% and 99.11%, respectively. CK-19 presented the best performance for discriminating papillary thyroid carcinomas, followed by HBME-1 and Gal-3. In the TBS-2 cases, CK-19 and, subsequently, Gal-3 were important immunocytochemistry markers. Ultimately, CK-19 and HBME-1 on TBS-5 or TBS-6 cases demonstrated the best results.
The hierarchical structure of the CART model provides a diagnostic algorithm linked with the risk of malignancy at every step of the procedure. It also provides guidance on the use of ancillary examinations as it goes by simple, human understandable rules.
基于细胞块免疫细胞化学和细胞学结果,研究分类与回归树(CART)在甲状腺病变诊断中的潜力。
通过液基细胞学方法制备并评估了956例经组织学确诊的甲状腺结节患者病例(673例良性和283例恶性);另外制备4张玻片,分别进行细胞角蛋白19(CK-19)、半乳糖凝集素3(Gal-3)、赫克托·巴蒂福拉间皮细胞1(HBME-1)和甲状腺球蛋白染色。基于免疫细胞化学和细胞学诊断构建CART算法并用于评估。
诊断CART模型的主要重要因素为:细胞学结果、CK-19、Gal-3和HBME-1。细胞学诊断的敏感性和特异性分别为96.27%和88.26%(临界值:贝塞斯达系统3类[TBS-3])。引入免疫细胞化学和CART模型后,敏感性和特异性分别提高到98.88%和99.11%。CK-19在鉴别甲状腺乳头状癌方面表现最佳,其次是HBME-1和Gal-3。在TBS-2病例中,CK-19以及随后的Gal-3是重要的免疫细胞化学标志物。最终,TBS-5或TBS-6病例中的CK-19和HBME-1显示出最佳结果。
CART模型的层次结构在该过程的每个步骤都提供了与恶性风险相关的诊断算法。它还通过简单易懂的规则为辅助检查的使用提供指导。